Suchergebnisse - "Rendell, Marc S."

PubPharm (11)

1

Obesity and diabetes : the final frontier

enthalten in: Expert review of endocrinology & metabolism | 2023

von Rendell, M.

2

The journey from gene knockout to clinical medicine : telotristat and sotagliflozin

enthalten in: Drug design, development and therapy | 2019

von Rendell, M.

3

Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes : A randomized, open-label clinical trial

enthalten in: Diabetes, obesity & metabolism | 2018

von Hollander, P. | Carofano, W. | Lam, R. | +8

4

Efficacy and safety of sotagliflozin in treating diabetes type 1

enthalten in: Expert opinion on pharmacotherapy | 2018

von Rendell, M.

5

Albiglutide for the management of type 2 diabetes

enthalten in: Expert review of endocrinology & metabolism | 2018

von Rendell, M.

6

The safety of albiglutide for the treatment of type 2 diabetes

enthalten in: Expert opinion on drug safety | 2017

von Rendell, M.

7

Albiglutide : a unique GLP-1 receptor agonist

enthalten in: Expert opinion on biological therapy | 2016

von Rendell, M.

8

Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment : a randomised clinical trial

enthalten in: Diabetologia | 2015

von Kothny, W. | Lukashevich, V. | Foley, J. | +2

9

DPP-4 inhibitors : focus on safety

enthalten in: Expert opinion on drug safety | 2015

von Tella, S. | Rendell, M.

10

Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study) : 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial

enthalten in: The lancet. Diabetes & endocrinology | 2013

von Rigby, M. | DiMeglio, L. | Rendell, M. | +121

CommentIn: Lancet Diabetes Endocrinol. 2013 Dec;1(4):261-3. - PMID 24622404